$2.90 -0.10 (-3.33%) BioTime Inc - NYSE Amex Equities

Aug. 29, 2016 | 04:00 PM
Last Trade: 2.90
Trade Time: Aug 29 04:00 PM Eastern Daylight Time
Change: -0.10 (-3.33%)
Prev Close: 3.00
Open: 2.98
Bid: 2.81
Ask: 3.56
  1. No results found.
  1. Benzinga's Top Initiations

    Benzinga | Dec. 22, 2015 | 10:01AM EST
  2. Morning Market Losers

    Benzinga | Sep. 28, 2015 | 09:59AM EST
  3. BioTime's Clinical Grade Stem Cells From Subsidiary ES Cell International to Be Used in Planned CIRM-Funded Preclinical Studies of Huntington's Disease

    Benzinga | Apr. 27, 2015 | 09:05AM EST
  4. Asterias Biotherapeutics Announces Public Offering of Common Stock

    Benzinga | Feb. 4, 2015 | 16:38PM EST
  5. BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of Urine-Based Bladder Cancer Diagnostic

    Benzinga | Dec. 15, 2014 | 11:03AM EST
  6. UPDATE: BioTime Receives Authorization To Begin Pivotal Human Clinical Trial Of Renevia In Europe

    Benzinga | Nov. 4, 2014 | 07:20AM EST
  7. Sterne Agee Sees Trouble For Oil Patch Regional Banks

    Benzinga | Oct. 15, 2014 | 08:28AM EST
  8. BioTime Subsidiary, Asterias Biotherapeutics, And Cancer Research UK And Cancer Research Technology Partner For Clinical Trial Of Immunotherapy Vaccine For Lung Cancer

    Benzinga | Sep. 11, 2014 | 16:15PM EST
  9. BioTime Subsidiary Asterias Biotherapeutics Receives U.S. FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury

    Benzinga | Aug. 27, 2014 | 09:02AM EST
  10. BioTime's Subsidiary OncoCyte Corporation Publishes Data on the Gene FSIP1 as a Breast Cancer-Specific Marker

    Benzinga | Aug. 5, 2013 | 09:04AM EST
  11. Top Narrow Based Indexes For January 8, 2013

    Benzinga | Jan. 8, 2013 | 04:21AM EST
  12. Benzinga's Small Cap Movers for Monday November 19, 2012

    Benzinga | Nov. 19, 2012 | 12:53PM EST
  13. BioTime and BioTime Acquisition Corporation Announce Combined $10M Financing

    Benzinga | Nov. 15, 2012 | 09:40AM EST
  14. UPDATE: BioTime, Geron Enter Deal on Stem Cell Assets

    Benzinga | Nov. 15, 2012 | 09:22AM EST
  15. BioTime Announces Non-Binding Letter of Intent with Geron Regarding Stem Cell Assets

    Benzinga | Nov. 15, 2012 | 09:16AM EST
Trading Center